Wockhardt UK, Wrexham
OVERVIEW
| Established in the
year: |
1950 |
| Facility Area: |
16,000 m2 |
| Dosage forms: |
Small Volume Parenterals - SVP
(cartridges, vials and ampoules)
Lyophilisation |
| Regulatory approval: |
USFDA / MHRA (other RoW approvals) |
Wockhardt UK has a comprehensive, FDA-approved manufacturing facility
for sterile injectables. This facility plays a strategic role in
the company's growth plans in:
- Driving growth through partnerships in contract manufacturing
- Being an injectable manufacturing base and centre of excellence
for global markets.
Over several decades, Wockhardt UK has established
its expertise in manufacturing injectables such as cartridges, vials
and ampoules (including lyophilised forms) in a variety of sizes.
Given its resources, it is not surprising that Wockhardt UK is the
partner of choice for reputed international companies for contract
manufacturing. With our credentials, we are currently investing
in a new sterile suite that will boast an additional 90 square metres
of lyophilisation capacity, with a state-of-the-art combination
filling line for vials and ampoules. The new sterile suite will
be ready and available by the end of 2009.
Wockhardt UK is also utilised as a gateway to our comprehensive
network of facilities in India. Our business and project managers,
together with our local teams in India, are able to manage your
molecule to meet your supply chain and business needs.
|
